WebJun 23, 2024 · Goldfinch Bio’s TRACTION-2 clinical research trial is evaluating an investigational precision medicine, GFB-887, for the potential treatment of TRMCD and FSGS. The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to kidney diseases caused by podocyte injury. WebMar 8, 2024 · Another TRPC5 inhibitor GFB-887 developed by Goldfinch Bio is in phase 1 clinical trial for the treatment of kidney disease (NCT number: NCT03970122). Among TRPC5 inhibitors, clemizole (CMZ) and HC-070 represent two distinct classes in terms of chemical structures. CMZ is a benzimidazole-derived H1 antagonist that can inhibit TRPC5.
(PDF) Safety and Efficacy of GFB-887, a TRPC5 Channel …
WebAug 15, 2024 · By showing that GFB-887 can protect human podocytes in transplanted organoids, these findings confirm the preclinical efficacy of the drug and establish its human relevance. The study also shows ... WebAug 10, 2024 · About GFB-887. GFB-887 is a once-daily, oral TRPC5 ion channel inhibitor in clinical development for the treatment of kidney diseases, including FSGS, TR-MCD and DN. TRPC5 is a calcium-permeable ... flights from phx to rsw
GFB-887 on Nephrotic Syndrome and Kidney Diseases and ...
WebJun 1, 2024 · FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects. Official Title: A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects. Secondary IDs: 8391348 [Covance] Study Status. WebFeb 28, 2024 · Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS) WebFeb 3, 2024 · It intends to evaluate GFB-887 to treat mood and anxiety disorders and expects to share details regarding the development in the second half of the year. Goldfinch Bio’s assignment estate will receive an upfront payment of $15m and is eligible for milestone payments of up to $520m for each licensed TRPC4/5 candidate, from which $410m … cherry and spoon sculpture